SPERO BIOPHARMA
Spero Biopharma is developing Ladostigil an innovative treatment for Mild Cognitive Impairment. Spero Biopharma was founded by Prof. Marta Weinstock-Rosin, a world-renowned researcher of Alzheimer's disease. Prof. Weinstock-Rosin is the inventor of Exelon®, a blockbuster drug for the treatment of Alzheimer’s disease, and a professor emeritus at the Hebrew University’s School of Pharmacy-Institute for Drug Research in the Faculty of Medicine.
SPERO BIOPHARMA
Industry:
Biopharma Biotechnology Health Care Wellness
Founded:
2019-06-01
Address:
Tel Aviv, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.sperobio.com
Status:
Active
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Content Delivery Network SSL By Default HSTS Google Google Cloud Google Apps For Business Sectigo SSL
Similar Organizations
CannaPowder
CannaPowder is a bio-pharma company dedicated to developing and applying innovative technology.
Etern
Etern is a biopharma company.
NanoPaz Pharma
NanoPaz Pharma specializes in research, development, and testing of an innovative treatment and products for advancing women’s health.
Sebana Medical
Sebana Medical is a biopharmaceutical company that develops a new type of dermal filler.
Current Employees Featured
Founder
Official Site Inspections
http://www.sperobio.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Spero Biopharma"
Home | Spero Biopharma
Spero Biopharma Ltd. was founded by Prof. Marta Weinstock-Rosin, a world-renowned inventor and researcher who invented Exelon®, a blockbuster drug for the treatment of Alzheimer’s …See details»
Spero Biopharma - Crunchbase Company Profile & Funding
Spero Biopharma is developing Ladostigil an innovative treatment for Mild Cognitive Impairment. Spero Biopharma was founded by Prof. Marta Weinstock-Rosin, a world-renowned researcher …See details»
Spero Biopharma - Overview, News & Similar companies - ZoomInfo
View Spero Biopharma (www.sperobio.com) location in Tel Aviv, Israel , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Spero Biopharma - Company Profile - Tracxn
Oct 22, 2024 Spero Biopharma ranks 3rd among 3 active competitors. 2 of its competitors are funded Overall, Spero Biopharma and its competitors have raised over $17M in funding across …See details»
Spero Biopharma Reviews | Read Client Reviews of Spero Biopharma.
Read reviews of Spero Biopharma. Write and share your personal story. Your experience will help others make the right buying decision.See details»
Spero Biopharma - Contacts, People & Board | Startup Nation Finder
Your organization type * -- select an option -- Startup Investor Hub (accelerator, community or similar) Corporation Job seeker Consultant or service provider SME (Small and medium-sized …See details»
Spero
W e’ve solved the key roadblocks to the industrial use of cell-free metabolic engineering. We're hitting the ground running with a reaction comprising nearly 70 enzymes. Why cell-free? …See details»
Spero Therapeutics - Crunchbase Company Profile & Funding
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient …See details»
Spero Therapeutics - The Org
Spero Therapeutics (Nasdaq: SPRO) is a multi-asset pre-commercial stage biopharmaceutical company in Cambridge, Mass. We are highly committed to advancing novel treatment …See details»
Spero Oncology - Crunchbase Company Profile & Funding
Spero Oncology has joined Veristat, a US-based full service CRO with over 20 years of experience supporting pharmaceutical, biotechnology and medical device firms throughout the …See details»
Spero Therapeutics, Inc. - AnnualReports.com
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) …See details»
Spero Biopharma Ltd.: 药物管线，专利，临床试验 - 智慧芽新药情 …
了解Spero Biopharma Ltd.公司的药物管线，治疗领域，技术平台，以及它的。See details»
Spero Therapeutics, Inc. (SPRO) Company Profile & Overview
Nov 2, 2017 Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) …See details»
Meet Spero, a biotech hopeful with Roche's blessing and a novel ...
Apr 9, 2014 With seed funding from Atlas Venture and an early-stage partnership with Roche, startup Spero Therapeutics is striking out with a novel approach to drug-resistant bacteria …See details»
Archive - The adventures of Spero Bio - sperobio.substack.com
Full archive of all the posts from The adventures of Spero Bio.See details»
Spero Biopharma - Foreign Startup | Startup Nation Finder
Your organization type * -- select an option -- Startup Investor Hub (accelerator, community or similar) Corporation Job seeker Consultant or service provider SME (Small and medium-sized …See details»
Spero Therapeutics Provides Corporate Update and 2024 Outlook
Jan 5, 2024 --Spero Therapeutics, Inc., a multi-asset, clinical-stage, biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi …See details»
Ourobio - Using synthetic biology to create the circular economy.
Ourobio began as an academic research project called Transfoam in early 2019 and was spun out in March 2020 with the goal of reducing microplastic pollution and the barriers to …See details»
Spero Biopharma - Foreign Startup | Startup Nation Finder
Your organization type * -- select an option -- Startup Investor Hub (accelerator, community or similar) Corporation Job seeker Consultant or service provider SME (Small and medium-sized …See details»
Spero Therapeutics Provides Corporate Update and 2024
Jan 5, 2024 In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in...See details»